Furthermore, fruquintinib can correct the immune escape microenvironment of tumor cells, mainly by inhibiting PD-L1 expression, inhibiting tumor release of inflammatory factors and immunosuppressive factors such as IL6/IL-10/VEGFR, and inhibiting bone marrow-derived suppressor cells. The gene discussed is KDR; the disease is neoplasm.